Locations:
Search IconSearch
July 14, 2017/Cancer

Well-Differentiated Lipomatous Tumors: A Case Series (Video)

Soft tissue pathology service’s most common consult

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never looks for lipoblasts when examining a well-differentiated fatty tumor.

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never bothers to identify lipoblasts when examining a well-differentiated fatty tumor.

In the final case, he examines a large retroperitoneal mass from an elderly patient and highlights the importance of examining the slide’s periphery in order to identify any well-differentiated liposarcomatous components. Find out why Dr. Goldblum argues that the type of spindle cell sarcoma is inconsequential in this case in the video below:

Advertisement

Pathology Insights: Well-Differentiated Lipomatous Tumors with John Goldblum, MD

The accurate diagnosis, grading and staging of benign and malignant soft tissue neoplasms, as well as mesenchymal neoplasms of the skin and parenchymal organs, can be challenging. Cleveland Clinic’s soft tissue pathology service, led by Karen Fritchie, MD, offers consultations on some of the most difficult cases in soft tissue pathology as well as a fellowship program and continuing medical education opportunities for practicing pathologists.

Advertisement

Related Articles

Dr. Holly Pederson
July 25, 2024/Cancer/Research
Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Reviewing dental scans
July 8, 2024/Cancer
A Call for More Interdisciplinary and Preventive Care in New Osteoradionecrosis Guidelines

New guidelines offer insight into emerging therapies, dental issues and more

Dr. AlHilli
July 3, 2024/Cancer/Patient Support
Prehabilitation Program Aims to Improve Outcomes for Older Patients with Ovarian or Pancreatic Cancer

Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy

Dr. Nahleh
June 26, 2024/Cancer/Patient Support
Systemic Treatment a Major Factor Impacting Survival of Patients with Breast Cancer with Brain Metastasis

Research demonstrates improved overall survival for patients receiving comprehensive treatment for breast cancer in addition to radiation or surgical intervention for brain cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

Ad